Background: The increasing demand for pulmonary retransplantation (re-LTx) raises ethical issues on the correct allocation of the scarce donor pool. Thus, we performed a thorough review of the current results for re-LTx in the Nordic countries.
Methods: Seventy-five patients with a median age of 50 years (range, 22 to 64 years) underwent re-LTx from 1992 until June 2013, of which 53 had single re-LTx, 21 had double re-LTx, and 1 patient underwent a heart-lung retransplantation. Primary graft dysfunction (PGD) was the primary indication in 9 cases, bronchiolitis obliterans syndrome (BOS) in 62 cases, and airway complications in 4 cases.
Results: Patients who underwent re-LTx in the period 1992 to 1999 (n = 16) had a 1-year survival of 37.5% (95% confidence interval [CI], 19.9 to 70.6), whereas patients who underwent re-LTx in the period 2000 to 2013 (n = 64) had a 1-year survival of 81.0% (95% CI, 71.5 to 91.8). Corresponding 5-year survival was 25.0% (95% CI, 10.7 to 58.4) in the early era group (1992 to 1999) and 57.2% (95% CI, 44.3 to 73.7) in the more recent era group (2000 to 2013; p = 0.0151). Patients with BOS who underwent re-LTx in the period 1992 to 1999 (n = 13) had a 1-year survival of 38.5% (95% CI, 19.3 to 76.5), whereas patients with BOS who underwent re-LTx in the period 2000 to 2013 (n = 49) had a 1-year survival of 85.4% (95% CI, 75.9 to 96.0). Corresponding 5-year survival was 23.1% (95% CI, 8.6 to 62.3) in the early era group (1992 to 1999) and 56.1% (95% CI, 41.9 to 75.2) in the more recent era group (2000 to 2013; p = 0.0199). The cumulative incidence among patients who underwent re-LTx because of BOS and developed BOS again after re-LTX was analyzed. The cumulative incidence curves for time periods 1992 to 1999 and 2000 to 2013 are not statistically different for repeat BOS (p = 0.5087), but they are highly significant for time periods among patients who died (p = 0.02381).
Conclusions: Results for re-LTx have improved over time, especially when BOS is the primary indication. The cumulative incidence among patients who underwent re-LTx because of BOS and developed repeat BOS after re-LTX showed equal risk between 1992 to 1999 and 2000 to 2013 in the aspect of developing repeat BOS, but in the later era the patients had a significantly higher chance of surviving.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.athoracsur.2015.01.052 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Off-pump lung re-transplantation avoiding clamshell thoracotomy is feasible and safe: a single-center experience.
J Thorac Dis
October 2023
Department of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium.
Article Synopsis
- Lung re-transplantation (re-LTx) is a treatment option for patients with serious lung graft issues, and this study focuses on the safety and feasibility of a less invasive surgical technique that avoids a clamshell incision.
- A total of 42 patients were analyzed, with findings indicating that the off-pump method led to shorter surgery times and lower rates of severe primary graft dysfunction compared to more invasive techniques using clamshell incisions.
- Both surgical approaches showed similar long-term survival rates, suggesting that the off-pump method could be a viable option for certain patients needing re-LTx.
Lung transplantation for late-onset non-infectious chronic pulmonary complications of allogenic hematopoietic stem cell transplant.
Respir Res
April 2021
Ajmera Transplant Centre and Toronto Lung Transplant Program, Toronto General Hospital, Toronto, Canada.
Background: Late onset non-infectious pulmonary complications (LONIPCs) following allogenic hematopoietic stem cell transplantation (allo-HSCT) confer a significant mortality risk. Lung transplantation (LTx) has the potential to provide survival benefit but the impact of prior allo-HSCT on post-LTx outcomes is not well studied.
Methods: This retrospective, single-centre cohort study assessed the post-LTx outcomes of adults with LONIPCs of allo-HSCT.
Impact of allograft ischemic time on long-term survival in lung transplantation: a Swedish monocentric study.
Scand Cardiovasc J
October 2020
Department of Cardiothoracic Surgery, Skåne University Hospital, Lund University, Lund, Sweden.
The influence of allograft ischemic time (IT) on short- and long-term mortality remains under debate in lung transplantation (LTx). Due to a scarcity in donors, better understanding of IT might improve the outcome after LTx. Between January 1990 and June 2016; 307 patients underwent LTx at Lund university hospital, Sweden.
View Article and Find Full Text PDFABO-identical matching has no superiority in long-term survival in comparison to ABO-compatible matching in lung transplantation.
J Cardiothorac Surg
January 2019
Dept. of Cardiothoracic Surgery, Lund University Hospital, Lund University, 221 85, Lund, Sweden.
Background: Even though identical blood group matching between recipient and donor is preferred, it is still not clear by how much this improves the outcome for patients who received a lung transplant (LTx), or whether there is any survival benefit. Earlier studies have yielded ambiguous results and few have investigated long-term survival. The aim of this study is, therefore, to explore the different outcomes of identical and compatible recipient and donor blood group matching to determine whether identical matching is superior (LTx).
View Article and Find Full Text PDFDouble lung, unlike single lung transplantation might provide a protective effect on mortality and bronchiolitis obliterans syndrome.
J Cardiothorac Surg
November 2017
Department of Cardiothoracic Surgery, Skåne University Hospital, Lund University, Lund, Sweden.
Background: Survival after lung transplantation (LTx) is often limited by bronchiolitis obliterans syndrome (BOS).
Method: Survey of 278 recipients who underwent LTx. The endpoint used was BOS (BOS grade ≥ 2), death or Re-lung transplantation (Re-LTx) assessed by competing risk regression analyses.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!